SJS Investment Consulting’s Amphastar Pharmaceuticals AMPH Stock Holding History

SJS Investment Consulting’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122	Buy	+6	New	+$121	﹤0.01%	2571
2025 Q1	–	Sell	-1	Closed	-$38	–	1604
2024 Q4	$38	Hold	1	–	–	﹤0.01%	1567
2024 Q3	$49	Hold	1	–	–	﹤0.01%	1618
2024 Q2	$40	Sell	1 -1	-50%	-$41	﹤0.01%	1627
2024 Q1	$88	Sell	2 -3	-60%	-$155	﹤0.01%	1582
2023 Q4	$310	Buy	5 +1	+25%	+$53	﹤0.01%	1363
2023 Q3	$184	Buy	4 +2	+100%	+$109	﹤0.01%	1469
2023 Q2	$115	Buy	2 +1	+100%	+$44	﹤0.01%	1502
2023 Q1	$38	Hold	1	–	–	﹤0.01%	1537
2022 Q4	$28	Hold	1	–	–	﹤0.01%	1566
2022 Q3	$0	Buy	+1	New	+$33	﹤0.01%	1021

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SJS Investment Consulting's AMPH Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2026: 6 shares worth $122. The stake represents ﹤0.01% of the portfolio and ranks #2571 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in AMPH as recently as Q4 2024.

SJS Investment Consulting first reported a position in AMPH in Q3 2022 and has held it in 11 quarters since. The position peaked at $310 in Q4 2023. 211 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

SJS Investment Consulting held 6 shares of Amphastar Pharmaceuticals worth $122 as of Q2 2026.
Amphastar Pharmaceuticals was a new SJS Investment Consulting position in Q2 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2571 holding.
SJS Investment Consulting first reported a position in Amphastar Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
SJS Investment Consulting's Amphastar Pharmaceuticals position peaked at $310 in Q4 2023.
211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.